We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bévacizumab et temsirolimus: quel apport dans la stratégie de prise en charge du cancer du rein métastatique ?
- Authors
Ravaud, A.; Bernhard, J.; Ferrière, J.
- Abstract
Bevacizumab and temsirolimus are two drugs recently developed and integrated in the first-line therapeutic management of patients with advanced ormetastatic renal cell carcinoma. Bevacizumab, a monoclonal antibody directed against circulating VEGF, has shown a significant benefit in progression-free survival during a randomized phase III trial in comparison to alpha interferon (5.4 to 10.2 months; HR: 0.63; P < 0.0001). Temsirolimus, an agent that inhibits the mTOR pathway, has shown a significant gain in overall survival, in a randomized phase III trial conducted in a population of patients with poor risk feature of metastatic renal cell carcinoma, compared to alpha interferon (7.3 to 10.9 months; HR: 0.73; P < 0.0069).
- Subjects
BEVACIZUMAB; RENAL cell carcinoma; CANCER treatment; MONOCLONAL antibody probes; INTERFERONS; CANCER patients
- Publication
Oncologie (Tech Science Press), 2008, Vol 10, Issue 11, p653
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-008-0964-6